{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:10:56Z","timestamp":1780697456086,"version":"3.54.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The non-NHS funded clinical work described was funded by the Batten Disease Family Association."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/Objectives<\/jats:title>\n                <jats:p>CLN2 Batten Disease is a fatal neurodegenerative condition of childhood associated with retinal dystrophy and blindness. Intracerebroventricular infusion of rhTPP1 greatly slows the rate of neurodegenerative decline but not retinopathy. Intravitreal rhTPP1 is known to slow retinal degeneration in a canine model of CLN2. We report a first-in-man controlled clinical trial of intravitreal rhTPP1 for CLN2 associated retinal dystrophy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Subjects\/methods<\/jats:title>\n                <jats:p>8 children aged 5\u20139 with CLN2 Batten Disease were prospectively enroled. Severely affected patients were preferentially selected, provided that vision was better than no perception of light. Children underwent 8 weekly intravitreal injections of rhTPP1 (0.2\u2009mg in 0.05\u2009ml) into the right eye for 12\u201318 months. The left eye was untreated and acts as a paired control. The primary outcome was safety based on the clinical detection of complications. A secondary outcome was paracentral macular volume (PMV) measured by spectral domain OCT. Linear regression\/paired t tests were used to compare rates of decline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No severe adverse reactions (uveitis, raised IOP, media opacity) occurred. The mean baseline PMV was 1.28\u2009mm<jats:sup>3<\/jats:sup>(right), 1.27\u2009mm<jats:sup>3<\/jats:sup>(left). 3 of the youngest patients exhibited bilateral progressive retinal thinning (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), whereas retinal volume was stable in the remaining 5 patients. In the 3 patients undergoing retinal degeneration, the rate of PMV loss was slower in the treated vs. untreated eye (<jats:italic>p<\/jats:italic>\u2009=\u20090.000042, <jats:italic>p<\/jats:italic>\u2009=\u20090.0011, <jats:italic>p<\/jats:italic>\u2009=\u20090.00022).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Intravitreal rhTPP1 appears to be a safe and effective treatment for CLN2 related retinopathy however commencement of treatment early in the course of disease is more likely to be efficacious.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41433-023-02859-4","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T09:02:26Z","timestamp":1701680546000},"page":"1176-1182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8207-2678","authenticated-orcid":false,"given":"James","family":"Wawrzynski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rodriguez","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-3911","authenticated-orcid":false,"given":"Dorothy Ann","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Whiteley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-6122","authenticated-orcid":false,"given":"Paul","family":"Gissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5250-6404","authenticated-orcid":false,"given":"Robert H.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"2859_CR1","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.bbadis.2015.05.011","volume":"1852","author":"SE Mole","year":"2015","unstructured":"Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochimica et Biophysica Acta (BBA)-Mol Basis Dis. 2015;1852:2237\u201341.","journal-title":"Biochimica et Biophysica Acta (BBA)-Mol Basis Dis"},{"key":"2859_CR2","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N, de Los Reyes E, Gissen P, Ballon D, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N. Engl J Med. 2018;378:1898\u2013907.","journal-title":"N. Engl J Med"},{"key":"2859_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","volume":"2","author":"M Nickel","year":"2018","unstructured":"Nickel M, Simonati A, Jacoby D, Lezius S, Kilian D, Van de Graaf B, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018;2:582\u201390.","journal-title":"Lancet Child Adolesc Health"},{"key":"2859_CR4","doi-asserted-by":"publisher","first-page":"e73128","DOI":"10.1371\/journal.pone.0073128","volume":"8","author":"A Orlin","year":"2013","unstructured":"Orlin A, Sondhi D, Witmer MT, Wessel MM, Mezey JG, Kaminsky SM, et al. Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function. PLoS One. 2013;8:e73128.","journal-title":"PLoS One"},{"key":"2859_CR5","doi-asserted-by":"publisher","first-page":"108130","DOI":"10.1016\/j.exer.2020.108130","volume":"197","author":"RE Whiting","year":"2020","unstructured":"Whiting RE, Pearce JW, Vansteenkiste DP, Bibi K, Lim S, Kick GR, et al. Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis. Exp Eye Res. 2020;197:108130.","journal-title":"Exp Eye Res"},{"key":"2859_CR6","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/s41433-021-01594-y","volume":"35","author":"DA Thompson","year":"2021","unstructured":"Thompson DA, Handley SE, Henderson RH, Marmoy OR, Gissen P. An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy. Eye. 2021;35:2438\u201348.","journal-title":"Eye"},{"key":"2859_CR7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.oret.2020.01.011","volume":"4","author":"KD Kovacs","year":"2020","unstructured":"Kovacs KD, Patel S, Orlin A, Kim K, Van Everen S, Conner T, et al. Symmetric age association of retinal degeneration in patients with CLN2-associated batten disease. Ophthalmol Retin. 2020;4:728\u201336.","journal-title":"Ophthalmol Retin"},{"key":"2859_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/cts.12925","volume":"14","author":"A Kim","year":"2021","unstructured":"Kim A, Grover A, Hammon K, de Hart G, Slasor P, Cherukuri A, et al. Clinical pharmacokinetics and pharmacodynamics of cerliponase alfa, enzyme replacement therapy for CLN2 disease by intracerebroventricular administration. Clin Transl Sci. 2021;14:635\u201344.","journal-title":"Clin Transl Sci"},{"key":"2859_CR9","unstructured":"Loh YP Mechanisms of intracellular trafficking and processing of proproteins. CRC Press; 1992."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02859-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T14:05:35Z","timestamp":1712844335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02859-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2859"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02859-4","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}